The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Taking it for 18 months??
If you look at his history he also reviewed Fruitflow back in 2017!
Bantam
Thanks adm04 that’s what I think I was looking for.
This was another open offer from 2011-
PROVEXIS - OPEN OFFER
PROVEXIS is proposing an Open Offer on the following basis:
1 New Ordinary share for every 10 Existing Ordinary shares held at an Issue Price of 1.5 pence per New Ordinary share.
Hi. I can see these dates on my share dealing platform.this was demerger 2013
1 New Science in Sport Limited (SiS) share for every 100 Existing Provexis PLC (Provexis) shares held as at 5pm on 6th August 2013, being the Record Date.
This was 2009 open offer
PROVEXIS is proposing an Open Offer on the following basis:
1 New Ordinary share for every 12 Existing Ordinary shares held at an Issue Price of 2.5 pence per New Ordinary share.
Seems like yesterday lol, oh well can only go back to 2012 I need to go a to 2009 or there abouts
Thanks again ??
You are going back a bit....
Best you check back on the website.
https://www.provexis.org/regulatory-news/
Thanks gixer,
Was there another one where We got some shares for 2.5p and a quota of SIS shares ? I’m just trying to recap as Iv changed brokers and laptops and lost all info on Pxs and what my average is.
https://otp.investis.com/clients/uk/provexis_plc/rns/regulatory-story.aspx?cid=1569&newsid=1351875
Anyone know what the ratio and the date this occurred?
Thanks
Gixer,
Very good post mate. Well summarized everything. The link shows why DSM did not reply to the e-mail mention about the COVID-19 link with fruitflow. Hope they will act fast to save lives from this horrible virus. The share price will follow the path once they act fast. Good time time to come soon.
Hello guys, long time...has it finally woken up?
Buffet says don’t hold an investment for a day if you are not willing to hold for 10years - something like that anyway. We must be close to that now!
If we are getting close to bluecap approval this could be the game changer. Pxs have said in their rns’s over the past couple years that it could lead to significant orders at substantial multiples or existing sales.
Let’s say that multiple is just 10x to start with. 10x our current income from the agreement with DSM would be nice...
Now with corona virus, this could lead to real demand for the product, especially in China.
Let’s see how this plays out
Have been in a long time , too embarrassed to mention .
I do believe in FF that is could go far with proper mass marketing . The science is credible and natural extracts . Win , Win
Sorry this sounds like a Trump tweet !!!
Happy Days are here (hopefully!) Again
Been keeping out of the Fruitflow / Covid-19 discussions as quite frankly the science is way above my head. I did however find wheelds link interesting and the connection to endothelial cells.
“What we’re saying is that maybe the best antiviral therapy is not actually an antiviral therapy. The best therapy might actually be a drug that stabilizes the vascular endothelial. We’re building a drastically different concept.”
https://elemental.medium.com/coronavirus-may-be-a-blood-vessel-disease-which-explains-everything-2c4032481ab2
"Tomato Aqueous Extract Modulates the Inflammatory Profile of Immune Cells and Endothelial Cells"
https://pubmed.ncbi.nlm.nih.gov/26840280/
"These water-soluble tomato components were also found to inhibit angiotensin-converting enzyme (ACE) and to relax the vascular endothelium, the other important limbs of the cardiovascular system"
"This Fruitflow® inhibits the activation of macrophage and endothelial cells, which could help to reduce leucocyte recruitment and promote a reduction in tissue inflammation"
Fruitflow®: the first European Food Safety Authority-approved natural cardio-protective functional ingredient.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334395/
Lots more on endothelial cells in the above publication, all I need now is for someone to explain it all to me.
Alf
the 0.85 trades don’t total up to much so would expect at least the same again this week. If your prognosis is correct we’ll remain at current SP for a while with any pi wanting some having to pay 0.89 plus - if we get a positive RNS then things would have to reset re 0.85.
W$
Yes I see , So the claims will be ‘maintains healthy blood flow ‘ and lowers blood pressure ‘
"The two completed studies (a human study and an animal study) showed excellent results in use for Fruitflow®,
and BY-HEALTH intends to make its first blue cap submission to the SAMR for Fruitflow® in February 2019,
with a further blue cap submission envisaged later in 2019, both to include references to the Company’s
existing European Food Safety Authority (‘EFSA’) health claim for Fruitflow."
https://provexis.org/wp-content/uploads/2018/12/PXS_2018-11_Provexis_plc_30-Sep-18_interims_31-Dec-18.pdf
Sphinx, I am hoping that the studies are for more than one health claim. Guessing blood pressure reduction being one.
An earlier RNS did indicate to at least 2.
Read the article before you say:-
"Wheelds. Ramper of the year. Unfounded nonsense. IMO."
All of us need to let our family and friends know that Fruitflow protects us from blood clotting.
https://elemental.medium.com/coronavirus-may-be-a-blood-vessel-disease-which-explains-everything-2c4032481ab2
Gixer I’m not sure it has been delayed, in the interims they stated that 5 studies are complete 2 are ongoing and 2 will take place In 2020 9 in all , so as we discussed before do they need all 9 studies to be complete before Blue hat approval is given ! My gut feeling is that they don’t need all 9 approved ,but each study would add strength to the case for efficacy for ff.
"Although the article is a year old it could explain the delay for at least one health claim."
delay is the wrong word to use as we don't know that there is one. However it would be nice if the company could give us a bit more info on Blue Hat.
Thanks Bella,
Although the article is a year old it could explain the delay for at least one health claim.
"the review also suggested to relook health claims that require further research evidence. Six claims, which include “aids in lowering of blood pressure” ?and “aids in lowering of blood sugar”?, would be affected."
"Regulatory advice ?
Regulatory experts have advised manufacturers to halt the R&D of products that bear claims which may require additional scientific research. This was because these claims might not be approved eventually, thus, if manufacturers were to proceed with R&D of these products, their past efforts would go down the drain, Charles Diao, regulatory manager at US-China Health Products Association told NutraIngredients-Asia."
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020077747&_cid=P10-K9F8JJ-45635-1
Bella that article is 14 months old